BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32987153)

  • 1. Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy.
    Dolicka D; Sobolewski C; Gjorgjieva M; Correia de Sousa M; Berthou F; De Vito C; Colin DJ; Bejuy O; Fournier M; Maeder C; Blackshear PJ; Rubbia-Brandt L; Foti M
    Cell Mol Gastroenterol Hepatol; 2021; 11(2):597-621. PubMed ID: 32987153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.
    Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S
    BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
    Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M
    Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
    Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
    Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
    Moeini A; Torrecilla S; Tovar V; Montironi C; Andreu-Oller C; Peix J; Higuera M; Pfister D; Ramadori P; Pinyol R; Solé M; Heikenwälder M; Friedman SL; Sia D; Llovet JM
    Gastroenterology; 2019 Nov; 157(5):1383-1397.e11. PubMed ID: 31344396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
    He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
    Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.
    Yang L; Inokuchi S; Roh YS; Song J; Loomba R; Park EJ; Seki E
    Gastroenterology; 2013 May; 144(5):1042-1054.e4. PubMed ID: 23391818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
    Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
    Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.
    Sohn BH; Park IY; Lee JJ; Yang SJ; Jang YJ; Park KC; Kim DJ; Lee DC; Sohn HA; Kim TW; Yoo HS; Choi JY; Bae YS; Yeom YI
    Gastroenterology; 2010 May; 138(5):1898-908. PubMed ID: 20038433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mice With Increased Numbers of Polyploid Hepatocytes Maintain Regenerative Capacity But Develop Fewer Hepatocellular Carcinomas Following Chronic Liver Injury.
    Lin YH; Zhang S; Zhu M; Lu T; Chen K; Wen Z; Wang S; Xiao G; Luo D; Jia Y; Li L; MacConmara M; Hoshida Y; Singal AG; Yopp A; Wang T; Zhu H
    Gastroenterology; 2020 May; 158(6):1698-1712.e14. PubMed ID: 31972235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP).
    Tran DDH; Koch A; Allister A; Saran S; Ewald F; Koch M; Nashan B; Tamura T
    Cell Signal; 2016 Dec; 28(12):1872-1880. PubMed ID: 27619201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential dual functional roles of the Y-linked RBMY in hepatocarcinogenesis.
    Kido T; Tabatabai ZL; Chen X; Lau YC
    Cancer Sci; 2020 Aug; 111(8):2987-2999. PubMed ID: 32473614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
    He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M
    J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
    Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
    J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
    Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
    Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of androgen/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks.
    Helms TH; Mullins RD; Thomas-Ahner JM; Kulp SK; Campbell MJ; Lucas F; Schmidt N; LeMoine DM; Getaneh S; Xie Z; Phelps MA; Clinton SK; Coss CC
    Sci Rep; 2021 Feb; 11(1):3646. PubMed ID: 33574348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Esparza-Baquer A; Labiano I; Sharif O; Agirre-Lizaso A; Oakley F; Rodrigues PM; Zhuravleva E; O'Rourke CJ; Hijona E; Jimenez-Agüero R; Riaño I; Landa A; La Casta A; Zaki MYW; Munoz-Garrido P; Azkargorta M; Elortza F; Vogel A; Schabbauer G; Aspichueta P; Andersen JB; Knapp S; Mann DA; Bujanda L; Banales JM; Perugorria MJ
    Gut; 2021 Jul; 70(7):1345-1361. PubMed ID: 32907830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-21-5p promotes NASH-related hepatocarcinogenesis.
    Rodrigues PM; Afonso MB; Simão AL; Islam T; Gaspar MM; O'Rourke CJ; Lewinska M; Andersen JB; Arretxe E; Alonso C; Santos-Laso Á; Izquierdo-Sanchez L; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Prip-Buus C; Banales JM; Rodrigues CMP; Castro RE
    Liver Int; 2023 Oct; 43(10):2256-2274. PubMed ID: 37534739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.
    Yang Y; Guo Y; Tan S; Ke B; Tao J; Liu H; Jiang J; Chen J; Chen G; Wu B
    Nat Commun; 2015 Jun; 6():7369. PubMed ID: 26077142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.